Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children.


Tashani, M; Rashid, H; Mulholland, K; Booy, R; (2016) Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children. Pneumonia (Nathan), 8. p. 16. ISSN 2200-6133 DOI: 10.1186/s41479-016-0016-8

Full text not available from this repository.

Abstract

Pneumococcal conjugate vaccine (PCV) has the potential to interact with other vaccines containing diphtheria toxin-like antigens (such as those found in the DTP vaccine) upon sequential administration. This is attributed to the similarity of the diphtheria toxoid antigen to the carrier protein used to make PCV, (known as cross reactive material [CRM]) to diphtheria toxin 197 or CRM197. The interaction could lead to enhanced immunogenicity of PCV as a result of a phenomenon called carrier priming, whereby DTP is given some weeks before the first dose of PCV. This phenomenon could be implemented in the immunisation schedule in developing countries and among vulnerable populations to enhance the immunogenicity of PCV, reduce the number of doses required, and produce a more cost-effective immunisation program in developing countries.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 28702295
URI: http://researchonline.lshtm.ac.uk/id/eprint/4086909

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
7Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item